Related references
Note: Only part of the references are listed.BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells
D. T. Saenz et al.
LEUKEMIA (2017)
HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist
S. G. T. Devaraj et al.
LEUKEMIA (2016)
Small-Molecule PROTACS: New Approaches to Protein Degradation
Momar Toure et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma
Caron Jacobson et al.
BLOOD (2016)
Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma
David Chiron et al.
BLOOD (2016)
Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma
Nakhle S. Saba et al.
BLOOD (2016)
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Shaokun Shu et al.
NATURE (2016)
Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity
Ruth Eichner et al.
NATURE MEDICINE (2016)
FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma
Y. Li et al.
ONCOGENE (2016)
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Kanak Raina et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
BET Bromodomain Inhibition Releases the Mediator Complex from Select cis-Regulatory Elements
Anand S. Bhagwat et al.
CELL REPORTS (2016)
Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib
Baohua Sun et al.
BLOOD (2015)
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
Michael L. Wang et al.
BLOOD (2015)
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Jing Lu et al.
CHEMISTRY & BIOLOGY (2015)
The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
Michela Boi et al.
CLINICAL CANCER RESEARCH (2015)
BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia
Jae-Seok Roe et al.
MOLECULAR CELL (2015)
NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler
Chen Shen et al.
MOLECULAR CELL (2015)
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
Philipp Rathert et al.
NATURE (2015)
BET inhibitor resistance emerges from leukaemia stem cells
Chun Yew Fong et al.
NATURE (2015)
Phthalimide conjugation as a strategy for in vivo target protein degradation
Georg E. Winter et al.
SCIENCE (2015)
Mantle cell lymphoma: evolving management strategies
Elias Campo et al.
BLOOD (2015)
The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells
Jenny Zhang et al.
BLOOD (2014)
Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells
Jiao Ma et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Unlocking New Therapeutic Targets and Resistance Mechanisms in Mantle Cell Lymphoma
Dolors Colomer et al.
CANCER CELL (2014)
Looping Back to Leap Forward: Transcription Enters a New Era
Michael Levine et al.
CELL (2014)
Ibrutinib for the Treatment of Mantle Cell Lymphoma
Alex F. Herrera et al.
CLINICAL CANCER RESEARCH (2014)
The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
Junwei Shi et al.
MOLECULAR CELL (2014)
Pharmacological and genomic profiling identifies NF-kappa B-targeted treatment strategies for mantle cell lymphoma
Rami Rahal et al.
NATURE MEDICINE (2014)
BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones
Tomohiko Kanno et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2014)
Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation
Friederike Itzen et al.
NUCLEIC ACIDS RESEARCH (2014)
Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA
Z. Zou et al.
ONCOGENE (2014)
Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
David Chiron et al.
CANCER DISCOVERY (2014)
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Jakob Loven et al.
CELL (2013)
Transcriptional Regulation and Its Misregulation in Disease
Tong Ihn Lee et al.
CELL (2013)
Super-Enhancers in the Control of Cell Identity and Disease
Denes Hnisz et al.
CELL (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Targeting pathological B cell receptor signalling in lymphoid malignancies
Ryan M. Young et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma
Silvia Bea et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
John P. Leonard et al.
BLOOD (2012)
Molecular pathogenesis of mantle cell lymphoma
Pedro Jares et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Pol II waiting in the starting gates: Regulating the transition from transcription initiation into productive elongation
Sergei Nechaev et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2011)
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
Patricia Perez-Galan et al.
BLOOD (2011)
New molecular targets in mantle cell lymphoma
Samir Parekh et al.
SEMINARS IN CANCER BIOLOGY (2011)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
Regulation and Function of NF-kappa B Transcription Factors in the Immune System
Sivakumar Vallabhapurapu et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
Functional proteomic profiling of AML predicts response and survival
Steven M. Kornblau et al.
BLOOD (2009)
Brd4 Coactivates Transcriptional Activation of NF-κB via Specific Binding to Acetylated RelA
Bo Huang et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Shared principles in NF-κB signaling
Matthew S. Hayden et al.
CELL (2008)
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Ali Mortazavi et al.
NATURE METHODS (2008)
Share Paper
